Maxygen, (FRA:MYN) Forward PE Ratio : 0.00 (As of May. 18, 2024)

View and export this data going back to . Start your Free Trial

What is Maxygen, Forward PE Ratio?

Maxygen,'s Forward PE Ratio for today is 0.00.

Maxygen,'s PE Ratio without NRI for today is 3.13.

Maxygen,'s PE Ratio for today is 3.13.

Maxygen, Forward PE Ratio Historical Data

The historical data trend for Maxygen,'s Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Maxygen, Forward PE Ratio Chart

Maxygen, Annual Data

Trend

Forward PE Ratio

Maxygen, Quarterly Data

Forward PE Ratio

Competitive Comparison of Maxygen,'s Forward PE Ratio

For the Biotechnology subindustry, Maxygen,'s Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Maxygen,'s Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Maxygen,'s Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Maxygen,'s Forward PE Ratio falls into.

Maxygen, Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.

Maxygen, (FRA:MYN) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .

Maxygen, Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Maxygen,'s Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Maxygen, (FRA:MYN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Maxygen, Inc. (FRA:MYN) » Definitions » Forward PE Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Maxygen, Inc., is incorporated in Delaware. It is a biotechnology company. It discovers and develops improved next-generation protein pharmaceuticals for the treatment of disease and serious medical conditions. The Company's MAXY-G34 product candidate has been designed to be an improved next-generation pegylated, G-CSF for the treatment of chemotherapy-induced neutropenia. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The Company completed a Phase IIa clinical trial for its MAXY-G34 product candidate for the treatment of chemotherapy-induced neutropenia in breast cancer patients in which MAXY-G34 was safe and effective in reducing chemotherapy-induced neutropenia with no serious adverse events, drug-related grade 3 or 4 adverse events or immunogenicity reported in any patient receiving MAXY-G34. Adverse events were consistent with known side effects of G-CSF molecules. The Company is subject to regulation by the FDA and comparable regulatory agencies in foreign countries with respect to any development and commercialization of its MAXY-G34 product candidate or any other products it may acquire in the future.